Celldex Therapeutics, Inc. (CLDX) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $2.54B is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCelldex Therapeutics, Inc. (CLDX) trades at $38.10 with MoonshotScore 28/100 (Grade F). Celldex Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies. Their drug candidates target inflammatory diseases and various forms of cancer.
Price as of Sep 11, 2026 · Last analyzed: Sep 2, 2026Celldex Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies. Their drug candidates target inflammatory diseases and various forms of cancer.
CLDX stock analysis for 2026: Analysts have set a consensus price target of $63.88 for Celldex Therapeutics, Inc., suggesting 67.7% upside from the current price of $38.10. The AI MoonshotScore is 28/100, in the Weak band (below 45) — a research signal, not a recommendation. Key factors: analyst coverage, AI-driven quantitative scoring.
CLDX: 2/3 scored disciplines lean bearish. Dominant signal: Business Quality weak.
How is this calculated? →Strongest side: Financial Safety (9/10, Strong). Weakest side: Business Quality (1/10, Negative).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Celldex Therapeutics, Inc. Company Overview
Who Are CLDX's Competitors?
CLDX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| SLS SELLAS Life Sciences Group, Inc. | $13.49 | -3.30% | $2.51B | 685-pillar |
| HRMY Harmony Biosciences Holdings, Inc. | $41.10 | -1.25% | $2.39B | 975-pillar |
| TRVI Trevi Therapeutics, Inc. | $15.91 | -4.39% | $2.26B | 665-pillar |
| MBX MBX Biosciences | $60.94 | -3.13% | $2.90B | 745-pillar |
| ARQT Arcutis Biotherapeutics, Inc. | $23.38 | -1.93% | $2.92B | 865-pillar |
| ADMA ADMA Biologics, Inc. | $9.42 | -0.31% | $2.18B | 925-pillar |
| AUPH Aurinia Pharmaceuticals Inc. | $16.11 | -0.86% | $2.07B | 905-pillar |
| ZLDPF Zealand Pharma A/S | $46.38 | -2.66% | $3.28B | 689-signal |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are the Key Risks for CLDX?
Negative return on equity (-48.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
Research confidence
Broad, current evidence sits behind this analysis.
- ● Scored on 67% of our measures
- ● Price is current
- ● Latest filing 36 days ago
- ● Covered by analysts
Why 28?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.52 Short-term liquidity (Financial Strength)
- +0.39 Bankruptcy-risk score (Financial Strength)
- +0.14 Net debt vs earnings (Financial Strength)
What is holding it back
- -0.78 Gross margin (Business Quality)
- -0.78 Operating margin (Business Quality)
- -0.78 Net margin (Business Quality)
Risk penalties applied
- -2.00 Loss-making with negative retained earnings
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 19 |
| 2026-08-26 | 19 |
| 2026-08-29 | 19 |
| 2026-09-01 | 21 |
| 2026-09-04 | 27 |
| 2026-09-07 | 21 |
| 2026-09-10 | 21 |
What changed?
The grade moved from 19 to 21 (+2).
What moved it up or down:
- +6 Financial Strength
- +2 Business Quality
- +1 Growth
Held back by:
- -3 Momentum
Over the same 18 days the stock moved -5.4%.
Insider Activity
Over the past six months, Celldex Therapeutics, Inc. insiders filed 18 SEC Form 4 transactions — 0 sales and 18 purchases. On net that is roughly 1.3M shares acquired (about $45.7M) — insiders putting money in tends to read as conviction.
CLDX Valuation & Market Position
With a $2.54B market cap, Celldex Therapeutics, Inc. sits in the mid-cap segment of the market. Analyst price targets span from $45.00 to $100.00, with a consensus of $63.88. At the current price of $38.10, that implies approximately 68% upside potential. Relative to its peer group, CLDX's quantitative score of 28/100 is below the peer average of 80/100.
Key Financial Metrics
Return on equity for Celldex Therapeutics, Inc. stands at -48.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -30.9%, showing how much profit it generates from its asset base. A current ratio of 8.92 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Celldex Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 18.74 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
Celldex Therapeutics, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 3.1% below estimates on average.
Quarterly Financial Performance: Celldex Therapeutics, Inc.
Revenue for Celldex Therapeutics, Inc. came in at $22K during Q2 FY2026, a 46.7% improvement versus the preceding quarter. The company recorded a net loss of $73.5M, with diluted EPS of $-0.94. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in its sector.
CLDX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $22,000 | -$74M | -$0.94 |
| Q1 FY2026 | $15,000 | -$79M | -$1.18 |
| Q4 FY2025 | $75,000 | -$81M | -$1.23 |
Q2 FY2026 · filed 6 Aug 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
CLDX Latest News
-
Celldex to Present at Upcoming Investor Conference
Yahoo! Finance: CLDX News · Sep 8, 2026
-
Celldex to Present at Upcoming Investor Conference
globenewswire.com · Sep 8, 2026
-
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)
prnewswire.com · Aug 24, 2026
-
California State Teachers Retirement System Acquires 21,233 Shares of Celldex Therapeutics, Inc. $CLDX
defenseworld.net · Aug 11, 2026
CLDX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CLDX.
Price Targets
Median: $60.50 (+67.7% from current price)
Source: FMP analyst consensus · as of Sep 11, 2026 · an estimate, not advice
CLDX MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. CLDX scores 28/100 (Grade F): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Latest News
Celldex to Present at Upcoming Investor Conference
Celldex to Present at Upcoming Investor Conference
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)
California State Teachers Retirement System Acquires 21,233 Shares of Celldex Therapeutics, Inc. $CLDX
What Investors Ask About Celldex Therapeutics, Inc. (CLDX)
What does the AI Score mean for CLDX?
CLDX holds an AI Score of 28/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is CLDX a good stock?
Stock Expert AI does not rate CLDX buy, sell or hold. Celldex Therapeutics, Inc. carries a MoonshotScore of 28/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the key factors to evaluate for CLDX?
Celldex Therapeutics, Inc. (CLDX) holds an AI score of 28/100 (low). Analysts target $63.88 (+68%). Not financial advice.
How frequently does CLDX data refresh on this page?
CLDX's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CLDX's recent stock price performance?
Celldex Therapeutics, Inc. (CLDX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CLDX overvalued or undervalued right now?
Celldex Therapeutics, Inc. (CLDX) is loss-making, so its trailing P/E is negative (-7.51x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Analysts target $63.88 (+68%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CLDX?
Yes, most major brokerages offer fractional shares of Celldex Therapeutics, Inc. (CLDX) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CLDX's earnings and financial reports?
Celldex Therapeutics, Inc. (CLDX) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for CLDX earnings announcements.
What should investors new to CLDX understand first?
Celldex Therapeutics, Inc. (CLDX) is worth researching across volatility, fundamentals, and industry context. Its current AI score is 28/100. With a market cap of $2.54B, it is a larger company which tends to be less volatile. Start with the Company Overview and MoonshotScore tabs for a structured introduction.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.